EXACT Sciences Co. (EXAS) Insider Sells $2,667,017.90 in Stock

EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 45,770 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $58.27, for a total value of $2,667,017.90. Following the sale, the insider now directly owns 237,820 shares of the company’s stock, valued at $13,857,771.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Graham Peter Lidgard also recently made the following trade(s):

  • On Wednesday, November 1st, Graham Peter Lidgard sold 45,775 shares of EXACT Sciences stock. The stock was sold at an average price of $53.60, for a total value of $2,453,540.00.
  • On Monday, October 2nd, Graham Peter Lidgard sold 81,025 shares of EXACT Sciences stock. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00.
  • On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of EXACT Sciences stock. The stock was sold at an average price of $40.81, for a total value of $3,088,623.23.

EXACT Sciences Co. (NASDAQ:EXAS) traded down $2.77 during trading hours on Monday, hitting $55.18. 2,360,000 shares of the company traded hands, compared to its average volume of 1,760,000. EXACT Sciences Co. has a twelve month low of $13.05 and a twelve month high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. During the same period last year, the business earned ($0.36) earnings per share. The firm’s revenue was up 158.4% on a year-over-year basis. sell-side analysts anticipate that EXACT Sciences Co. will post -1.12 EPS for the current year.

Several large investors have recently added to or reduced their stakes in EXAS. Fred Alger Management Inc. bought a new position in shares of EXACT Sciences in the second quarter valued at $84,177,000. Lord Abbett & CO. LLC lifted its holdings in EXACT Sciences by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after purchasing an additional 875,527 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in EXACT Sciences during the 2nd quarter valued at $29,450,000. Vanguard Group Inc. lifted its holdings in EXACT Sciences by 8.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after purchasing an additional 700,051 shares during the last quarter. Finally, Green Valley Investors LLC acquired a new stake in EXACT Sciences during the 2nd quarter valued at $20,892,000. 82.39% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently issued reports on EXAS. Robert W. Baird cut EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 target price for the company. in a research note on Monday, November 13th. Leerink Swann reaffirmed an “outperform” rating and set a $67.00 price target (up from $63.00) on shares of EXACT Sciences in a research note on Monday, November 13th. Bank of America raised their price target on shares of EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, November 29th. BTIG Research cut shares of EXACT Sciences from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 1st. Finally, Zacks Investment Research cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. EXACT Sciences has an average rating of “Buy” and an average price target of $50.58.

ILLEGAL ACTIVITY NOTICE: “EXACT Sciences Co. (EXAS) Insider Sells $2,667,017.90 in Stock” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/exact-sciences-co-exas-insider-sells-2667017-90-in-stock.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply